title: [Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin].
abstract: OBJECTIVE
  Streptococcus pneumoniae is the main etiological agent of community-acquired pneumonia. The aim of this work was to ascertain the resistance profiles of pneumococcus to penicillin and erythromycin and to analyse whether such profiles lead to different disease developments.
  
  
  METHODS
  A retrospective analysis was carried out in 75 cases of pneumococcal pneumonia corresponding to hospitalized patients. Comorbidity factors were evaluated including their influence on the appearance of resistance.
  
  
  RESULTS
  67 patients (89.3%) presented comorbidity factors. 49.3% isolates displayed some type of resistance: 38.6% to penicillin, 36% to erythromycin and 13.3% to cefotaxime. No relationship was observed between the severity of the pneumonia and antibiotic resistance. Complications and mortality were not influenced by the susceptibility of pneumococcus to antibiotics.
  
  
  CONCLUSIONS
  The increase in the resistance to antibiotics, especially erythromycin, makes betalactams the best choice for the treatment of pneumococcal pneumonia.
authors.affiliation: Servicio de Neumología. Hospital General Universitario de Valencia. España.
authors.forename: Francisco
authors.initials: F
authors.lastname: Sanz Herrero
authors.forename: Gustavo
authors.initials: G
authors.lastname: Juan Samper
authors.forename: Mercedes
authors.initials: M
authors.lastname: Ramón Capilla
authors.forename: Rafael
authors.initials: R
authors.lastname: Navarro Iváñez
authors.forename: Tomás
authors.initials: T
authors.lastname: Lloret Pérez
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002439:Cefotaxime / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D010403:Penicillin Resistance; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D004917:Erythromycin; D002439:Cefotaxime